Core--Thrombosis

目的：核心的总体目标是为SCOR的所有单个项目提供生化和血栓形成支持。该核心将负责与Badimon灌注室有关的血液血栓形成性研究的表现和评估，以及目前SCOR应用程序中不同项目开发所需的所有不同血液学和生化参数。临床项目（Dr. V. Fuster）包括大约500个灌注研究。糖尿病（n=50）和高脂血症（n=50）患者的队列将在基线和治疗开始后3、9和18个月进行研究；吸烟者将在基线和戒烟后4周进行研究。这些患者将在治疗开始后的基线、3、9和18个月监测TFPI、TF抗原和活性、c反应蛋白的血浆水平。此外，核心还将负责与逆转和妇女健康研究的研究人员合作获得的样品中TIPI和TF抗原及其活性的测定（见Dr. Fuster’s Project）。核心将负责参与临床项目（d.v. Fuster）的高脂血症、糖尿病和吸烟者的生化数据的测定和管理。该核心还将负责Taubman博士和Nemerson博士项目中描述的所有血液血栓形成性研究，以及该项目实验研究中TF抗原和活性、TIPI、c反应蛋白和肌钙蛋白- i的血浆水平的测定。Core还将监测陶布曼项目中动物的抗凝血水平（aPTT、PTT、TT）和血细胞计数（通过使用配备兽医软件的细胞计数器），以及哈佩尔博士项目中的胆固醇水平。

DESCRIPTION (Applicant's Abstract) Aims: The overall objective of the Core is to offer the biochemical and thrombosis support to all the individual projects of the SCOR. This Core will be responsible for the performance and evaluation of the studies involving blood thrombogenicity with Badimon perfusion chamber and all the different hematological and biochemical parameters required for the development of the different projects included in the present SCOR application. The Clinical Project (Dr. V. Fuster) includes approximately 500 perfusion studies. The cohorts of diabetic (n=50) and hyperlipidemic (n=50) patients will be studied at baseline and 3-, 9- and 18- months after treatment initiation; the smokers will be studied at baseline and 4-weeks after smoking cessation). These patients will be monitored for plasma levels of TFPI, TF antigen and activity, C-Reactive Protein at baseline, 3, 9 and 18-months after treatment initiation. In addition, the Core will also be responsible for the determination of TIPI and TF antigen and activity in the samples obtained through our collaboration with the investigators of the REVERSAL and WOMEN'S HEALTH STUDY (See Dr. Fuster's Project). The core will be responsible for the determination and management of the biochemical data of the hyperlipidemic, and diabetic and smokers involved in the Clinical Project (D. V. Fuster). The Core will also be responsible for all the blood thrombogenicity studies described in Dr. Taubman's and Nemerson's project as well as the determination of plasma levels of TF antigen and activity, TIPI, C-Reactive Protein and Troponin-I in the experimental studies of this project. The Core will also monitor the levels of anticoagulation (aPTT, PTT, TT) and the blood cell count (by using a cell counter equipped with veterinarian software) of the animals from Taubman's project and cholesterol levels from Dr. Harpel's project.